TETmedical™

FOR IMMEDIATE RELEASE

TETmedical Appoints Dr. Hooman Kamel and Dr. Evan Gerber as Medical Advisors

Leading Vascular Neurologist and Emergency Physician Bring Front-Line Stroke Expertise as TETmedical Advances NSE-FAST® Through Its Pivotal Study

Fair Haven, NJ and Ithaca, NY, November 10, 2026 - TETmedical, Inc., a clinical-stage medical diagnostics company developing rapid tools for diagnosing acute neurological injury, including ischemic stroke, based on its patented Tethered Enzyme Technology (TET), today announced that **Hooman Kamel, M.D., M.S.**, and **Evan Gerber, M.D.**, will serve as Medical Advisors to the Company. Dr. Kamel is a nationally recognized vascular neurologist and stroke researcher at Weill Cornell Medicine, and Dr. Gerber is a thought-leading emergency medicine physician practicing in Colorado.

Drs. Kamel and Gerber will advise TETmedical on clinical strategy, study design, and the integration of NSE-FAST® into emergency department workflows as the Company advances its lead product through a multi-center pivotal study, following the FDA's grant of Breakthrough Device Designation earlier this year.

"The value of a rapid blood test for ischemic stroke will ultimately be judged at the bedside, by the neurologists and emergency physicians who make time-critical treatment decisions every day," said **Dr. David Fischell**, Co-Founder and Chief Executive Officer of TETmedical. "Dr. Kamel is one of the most accomplished stroke researchers in the country, and Dr. Gerber brings the practical perspective of a front-line emergency physician. Together, they give us deep clinical insight across the full continuum of acute stroke care, from the emergency department to the neuro-ICU, and their guidance will be invaluable as we complete our pivotal study and prepare NSE-FAST for commercial launch."

"Despite major advances in stroke treatment, rapid and accurate diagnosis remains one of the field's greatest challenges, particularly for patients who present with subtle or nonspecific symptoms," said **Dr. Kamel**. "A fast, objective blood-based biomarker of brain injury could help clinicians identify these patients sooner and get them to the right therapy. I look forward to supporting TETmedical as it rigorously evaluates NSE-FAST in its pivotal study."

"Every shift, emergency physicians evaluate patients with dizziness and other neurologic complaints, and deciding which of them is having a stroke is one of the hardest calls we make," said **Dr. Gerber**. "NSE-FAST has the potential to give us a fast, objective answer at the point of care. I'm excited to join TETmedical and help ensure the test fits the realities of emergency medicine."

About Hooman Kamel, M.D., M.S.

Hooman Kamel, M.D., M.S., is the Helen and Albert Moon Professor of Neurology at Weill Cornell Medicine, where he serves as Chief of Neurocritical Care and Vice Chair for Research in the Department of Neurology, and as an Attending Neurologist at NewYork-Presbyterian Hospital. He also directs the Clinical and Translational Neuroscience Unit in the Feil Family Brain and Mind Research Institute.

Dr. Kamel's research focuses on stroke and atrial fibrillation. He is a Principal Investigator of the NIH-funded ARCADIA and ASPIRE trials, serves on the NIH StrokeNet Executive Committee, and chairs its Prevention Working Group. He has published more than 500 scientific papers, including in the *New England Journal of Medicine* and *JAMA*, and serves as Deputy Editor of *JAMA Neurology*.

His honors include the American Academy of Neurology's Michael S. Pessin Stroke Leadership Prize and the American Heart Association's Robert G. Siekert New Investigator Award.

Dr. Kamel received his B.A. from Harvard College, his M.D. from Columbia University Vagelos College of Physicians and Surgeons, and his M.S. from Columbia University. He completed his neurology residency and neurocritical care fellowship at the University of California, San Francisco, and is board certified in neurology and neurocritical care.

About Evan Gerber, M.D.

Evan Gerber, M.D., is an emergency medicine physician with Boulder Emergency Physicians, practicing at Boulder Community Health in Boulder, Colorado, and with Innova Emergency Medical Associates, where his practice focuses on rural and tribal health. As a Medical Advisor, Dr. Gerber will focus on the clinical application of NSE-FAST in emergency department patients with nonspecific neurologic symptoms such as dizziness, and will support the design of the Company's clinical studies.

Dr. Gerber completed his residency in emergency medicine at Denver Health Medical Center. He received his M.D. from New York University School of Medicine, where he was elected to the Alpha Omega Alpha Honor Medical Society, and his B.S. in Biochemistry, summa cum laude, from Arizona State University. He previously served as Resident Representative on the Board of the Colorado Chapter of the American College of Emergency Physicians.

ABOUT TETMEDICAL, INC.

TETmedical is a medical diagnostics company focused on developing rapid, near-patient in vitro diagnostic tools for acute neurological injury. The Company's lead product, NSE-FAST®, is designed to measure the functional enzymatic activity of Neuron Specific Enolase (NSE) in plasma as an aid in the diagnosis of acute ischemic stroke. NSE-FAST represents the lead program arising from TETmedical's patented Tethered Enzyme Technology platform, which the Company believes may have broader applications for diagnosis of acute neurological injury and other disease states.

On June 15, 2026, the FDA granted NSE-FAST Breakthrough Device Designation. TETmedical plans to initiate its multi-center pivotal study in the fourth quarter of 2026. For more information, please visit www.tetmedical.com.

FORWARD-LOOKING STATEMENTS

This press release contains forward-looking statements within the meaning of applicable securities laws, including statements regarding the anticipated contributions of the Company's medical advisors, the potential clinical utility of NSE-FAST®, and the Company's plans to initiate a multi-center pivotal study in the fourth quarter of 2026 and to pursue commercialization. These statements are based on management's current expectations and assumptions and are subject to a number of risks and uncertainties, including the Company's ability to initiate and complete clinical studies on anticipated timelines, obtain required regulatory authorizations, and secure adequate financing. Actual results may differ materially from those expressed or implied in these forward-looking statements. TETmedical undertakes no obligation to update forward-looking statements, except as required by applicable law.

FOR FURTHER INFORMATION, PLEASE CONTACT:

Dr. David Fischell | Co-Founder & Chief Executive Officer
Email: drfischell@tetmedical.com

Arjun Ishwar | Chief Commercial Officer
Email: aishwar@tetmedical.com

Website: www.tetmedical.com

# # #

#Stroke #IschemicStroke #EmergencyMedicine #Neurology #BrainInjury #NeuronSpecificEnolase #Dizziness #NeurologicalImpairment